VIR-3434

Phase 2Small molecule

VVir Biotechnology, Inc.

VIR-3434 is one of 74 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Chronic Hepatitis B Virus InfectionActive, not recruiting

Hepatitis D, ChronicActive, not recruiting

Chronic HepatitisPhase 1/Phase 2

Active, not recruiting

Chronic Hepatitis B Virus InfectionPhase 1

Active, not recruiting

Hepatitis D, ChronicPhase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 4

Incivek

Vertex Pharmaceuticals

Preclinical

10 5

Intron a

Sanofi

Preclinical

7 6

Roferon-a

Roche

Preclinical

3 7

VIR-3434

VVir Biotechnology, Inc.

Phase 2

2 8

Medrol

Pfizer

Preclinical

1 9

Dasabuvir

AbbVie

Preclinical

7 10

SOF/VEL

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Hepatic Impairment

NCT05484206

Q4 2029

Phase 2Recruiting

Chronic Hepatitis

NCT06216470

Q2 2032

Phase 2Active, not recruiting

Hepatitis D, Chronic

NCT05461170

Clinical

Trials by Indication[1]

Chronic Hepatitis2 trials

Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06216470·15 enrolled

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

Completed·VVir Biotechnology, Inc.·Phase 1/2·NCT05612581·33 enrolled

Chronic Hepatitis B Virus Infection2 trials

Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection

Completed·VVir Biotechnology, Inc.·Phase 1·NCT04423393·113 enrolled

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Active, not recruiting·VVir Biotechnology, Inc.·Phase 2·NCT04856085·244 enrolled

Hepatic Impairment1 trial

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Recruiting·VVir Biotechnology, Inc.·Phase 1·NCT05484206·144 enrolled

Vaccination1 trial

Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

Active, not recruiting·VVirion Therapeutics·Phase 1·NCT06070051·56 enrolled

Hepatitis D, Chronic1 trial

A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)

Active, not recruiting·VVir Biotechnology, Inc.·Phase 2·NCT05461170·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for VIR-3434. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VIR-3434 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VIR-3434. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vir Biotechnology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVir Biotechnology, Inc.

VIR-3434

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2029

Q2 2032

Trials by Indication[1]

Chronic Hepatitis2 trials

Chronic Hepatitis B Virus Infection2 trials

Hepatic Impairment1 trial

Vaccination1 trial

Hepatitis D, Chronic1 trial

References

Drug Info

Quick Facts

Related News